Xavier G Thomas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4948603/publications.pdf

Version: 2024-02-01

204 papers	14,682 citations	34016 52 h-index	19690 117 g-index
214 all docs	214 docs citations	214 times ranked	11591 citing authors

#	Article	IF	Citations
1	Isatuximab monotherapy in patients with refractory Tâ€acute lymphoblastic leukemia or Tâ€lymphoblastic lymphoma: Phase 2 study. Cancer Medicine, 2022, 11, 1292-1298.	1.3	10
2	Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review. Oncology and Therapy, 2022, , 1.	1.0	0
3	Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs, 2022, 27, 169-185.	1.0	1
4	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia, 2021, 35, 712-723.	3.3	10
5	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Advances, 2021, 5, 176-184.	2.5	56
6	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
7	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	1.7	4
8	Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication. Cancers, 2021, 13, 2272.	1.7	3
9	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138, 507-519.	0.6	40
10	Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nature Communications, 2021, 12, 3084.	5.8	38
11	CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e468-e469.	2.2	2
12	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer, 2021, 127, 4421-4431.	2.0	4
13	Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry. Leukemia Research, 2021, 111, 106673.	0.4	6
14	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica, 2021, 106, 1767-1769.	1.7	8
15	The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study. Blood, 2021, 138, 512-512.	0.6	9
16	Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study. Blood, 2021, 138, 215-215.	0.6	1
17	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study). Blood, 2021, 138, 2344-2344.	0.6	1
18	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 4440-4440.	0.6	2

#	Article	IF	Citations
19	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372.	0.6	13
20	Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers. Blood, 2021, 138, 4379-4379.	0.6	0
21	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 2351-2351.	0.6	3
22	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 698-698.	0.6	7
23	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88.	1.7	4
24	Alisertib: a new option for acute myeloid leukaemia. Lancet Haematology,the, 2020, 7, e87-e88.	2.2	0
25	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy, 2020, 20, 879-891.	1.1	2
26	Acute Promyelocytic Leukemia. Cancers, 2020, 12, 3718.	1.7	2
27	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances, 2020, 4, 1942-1949.	2.5	49
28	LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A â€˜REAL-LIFEâ€™ STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020020.	0.5	4
29	Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study. Leukemia and Lymphoma, 2020, 61, 2161-2167.	0.6	7
30	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 523-530.	0.9	15
31	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia, 2020, 34, 1730-1740.	3.3	21
32	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. Expert Review of Hematology, 2020, 13, 619-643.	1.0	7
33	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546.	0.6	62
34	Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy. Blood, 2020, 136, 23-24.	0.6	5
35	Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively. Blood, 2020, 136, 7-8.	0.6	1
36	Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS. Blood, 2020, 136, 1-2.	0.6	0

#	Article	IF	Citations
37	Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse. Blood, 2020, 136, 38-39.	0.6	2
38	Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica, 2019, 104, 113-119.	1.7	226
39	Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. Oncology and Therapy, 2019, 7, 121-130.	1.0	9
40	Epigenetic Silencing Affects<scp>l</scp>-Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research, 2019, 25, 2483-2493.	3.2	25
41	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. Cancers, 2019, 11, 570.	1.7	14
42	Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Advances in Therapy, 2019, 36, 870-879.	1.3	4
43	Acute Promyelocytic Leukemia: A History over 60 Yearsâ€"From the Most Malignant to the most Curable Form of Acute Leukemia. Oncology and Therapy, 2019, 7, 33-65.	1.0	48
44	Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. Leukemia Research, 2019, 76, 29-32.	0.4	2
45	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 131-142.	1.1	57
46	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood, 2019, 133, 280-284.	0.6	48
47	Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?. Lancet Haematology,the, 2018, 5, e128-e129.	2.2	1
48	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e211-e218.	0.2	5
49	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of Clinical Oncology, 2018, 36, 2514-2523.	0.8	99
50	A new signaling cascade linking BMP4, BMPR1A, Î"Np73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death and Disease, 2018, 9, 1011.	2.7	28
51	Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. Expert Opinion on Biological Therapy, 2018, 18, 1095-1106.	1.4	6
52	Successful pregnancies in patients with BCRâ€ABLâ€positive leukemias treated with interferonâ€alpha therapy during the tyrosine kinase inhibitors era. European Journal of Haematology, 2018, 101, 774-780.	1.1	17
53	A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia. Leukemia Research, 2018, 72, 7-11.	0.4	3
54	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica, 2018, 103, 2033-2039.	1.7	24

#	Article	IF	Citations
55	Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. Blood, 2018, 132, 865-867.	0.6	18
56	FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e545-e550.	0.2	19
57	Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience. Blood, 2018, 132, 4014-4014.	0.6	14
58	Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 237-240.	0.6	7
59	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70) Tj ETQq1 1 0.784314 rgBT /Over	0.6	12
60	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology, 2017, 35, 1223-1230.	0.8	37
61	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	13.9	1,443
62	Treatment of Elderly Patients With Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2017, 18, 2.	1.3	18
63	The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia. Expert Opinion on Drug Discovery, 2017, 12, 747-753.	2.5	7
64	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. Annals of Hematology, 2017, 96, 363-371.	0.8	9
65	The management and treatment of acute leukemias in the elderly population. Expert Review of Hematology, 2017, 10, 975-985.	1.0	7
66	Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. Oncology and Therapy, 2017, 5, 111-118.	1.0	8
67	Acute myeloid leukemia in the elderly (age 70 yr or older): longâ€term survivors. European Journal of Haematology, 2017, 98, 134-141.	1.1	9
68	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. PLoS ONE, 2017, 12, e0170160.	1.1	25
69	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World Journal of Stem Cells, 2017, 9, 227-234.	1.3	31
70	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	0.8	227
71	TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016009.	0.5	17
72	New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2016, 5, 127-131.	0.7	0

#	Article	IF	Citations
73	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Design, Development and Therapy, 2016, 10, 757.	2.0	19
74	HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017015.	0.5	22
75	Erythrocyte encapsulated <scp>l</scp>-asparaginase (GRASPA) in acute leukemia. International Journal of Hematologic Oncology, 2016, 5, 11-25.	0.7	20
76	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomeâ€“positive ALL. Blood, 2016, 128, 774-782.	0.6	243
77	Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2016, 5, 77-90.	0.7	6
78	The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert Opinion on Drug Discovery, 2016, 11, 1061-1070.	2.5	9
79	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 1044-1053.	13.9	270
80	Treating adults with acute lymphocytic leukemia: new pharmacotherapy options. Expert Opinion on Pharmacotherapy, 2016, 17, 2319-2330.	0.9	7
81	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematology,the, 2016, 3, e186-e195.	2.2	359
82	Blinatumomab in acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2016, 16, 251-253.	1.1	2
83	The safety of treatment options for elderly people with acute myeloid leukemia. Expert Opinion on Drug Safety, 2016, 15, 635-645.	1.0	2
84	Cidofovir in the Treatment of BK Virusâ€“Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 723-730.	2.0	61
85	HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. Journal of Infection, 2016, 72, 214-222.	1.7	32
86	Acute myeloid leukemia in the pregnant patient. European Journal of Haematology, 2015, , n/a-n/a.	1.1	10
87	Acute Myeloid Leukemia in the Elderly Patient: New Strategies. Rare Cancers and Therapy, 2015, 3, 1-11.	0.2	5
88	Toward effective targeted therapy for the treatment of adult acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2015, 4, 1-4.	0.7	0
89	Novel approaches to pediatric leukemia treatment. Expert Review of Anticancer Therapy, 2015, 15, 811-828.	1.1	2
90	Blinatumomab: a new era of treatment for adult ALL?. Lancet Oncology, The, 2015, 16, 6-7.	5.1	35

#	Article	IF	Citations
91	Acute myeloid leukemia in the pregnant patient. European Journal of Haematology, 2015, 95, 124-136.	1.1	19
92	The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. Leukemia Research, 2015, 39, 453-461.	0.4	8
93	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	5.1	129
94	Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 477-483.	0.2	18
95	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology,the, 2015, 2, e108-e117.	2.2	36
96	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 2015, 125, 3711-3719.	0.6	291
97	Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?. Lancet Oncology, The, 2015, 16, 1451-1453.	5.1	4
98	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, 2015, 100, e196-e199.	1.7	16
99	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9
100	Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: AÂSingle-Center Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S7-S13.	0.2	8
101	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. Annals of Hematology, 2015, 94, 1797-1806.	0.8	13
102	Higher percentage of CD34 + CD38â˜' cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 622-629.	0.6	9
103	Antibodyâ€based therapies in Bâ€cell lineage acute lymphoblastic leukaemia. European Journal of Haematology, 2015, 94, 99-108.	1.1	26
104	Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. Blood, 2015, 126, 1-1.	0.6	29
105	Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. Blood, 2015, 126, 451-451.	0.6	3
106	Supportive care in patients with acute leukaemia: historical perspectives. Blood Transfusion, 2015, 13, 205-20.	0.3	10
107	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood, 2014, 124, 1312-1319.	0.6	61
108	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 855-862.	0.6	16

#	Article	IF	Citations
109	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. American Journal of Hematology, 2014, 89, 410-416.	2.0	91
110	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	0.6	281
111	A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 68-72.	0.2	19
112	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. Blood, 2014, 124, 117-117.	0.6	27
113	Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia. American Journal of Case Reports, 2014, 15, 13-17.	0.3	1
114	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	0.6	313
115	Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. Biology of Blood and Marrow Transplantation, 2013, 19, 150-155.	2.0	140
116	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	0.8	68
117	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). Journal of Clinical Oncology, 2013, 31, 4424-4430.	0.8	78
118	Decitabine for the treatment of adult patients (age â‰¥65 years) with newly diagnosedde novoor secondary acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 305-314.	0.7	0
119	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	2.0	30
120	Mobilization of CD34+CD38-hematopoietic stem cells after priming in acute myeloid leukemia. World Journal of Stem Cells, 2013, 5, 196.	1.3	6
121	Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma, 2012, 53, 1068-1076.	0.6	50
122	DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opinion on Drug Discovery, 2012, 7, 1039-1051.	2.5	21
123	Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. Blood and Lymphatic Cancer: Targets and Therapy, 2012, , 57.	1.2	0
124	Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opinion on Investigational Drugs, 2012, 21, 871-878.	1.9	26
125	Acute myeloid leukemia in the elderly. International Journal of Hematologic Oncology, 2012, 1, 57-69.	0.7	1
126	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet, The, 2012, 379, 1508-1516.	6.3	839

#	Article	IF	Citations
127	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 2670-2677.	0.8	998
128	The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. European Journal of Cancer, 2012, 48, 360-367.	1.3	15
129	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.4	9
130	High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia. PLoS ONE, 2012, 7, e51527.	1.1	58
131	Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy. World Journal of Stem Cells, 2012, 4, 44.	1.3	7
132	Blast Asparagine Synthetase Deficiency in Acute Myeloid Leukemia. Blood, 2012, 120, 4333-4333.	0.6	0
133	Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 342-349.	0.2	9
134	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, 5099-5107.	0.6	50
135	Promyelocytic sarcoma of the sternum: a case report and review of the literature. The Korean Journal of Hematology, 2011, 46, 52.	0.7	11
136	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	0.6	52
137	<scp>l</scp>â€asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005â€01 randomized trial. British Journal of Haematology, 2011, 153, 58-65.	1.2	118
138	Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survivalâ€"A retrospective study of 42 adult cases. Leukemia Research, 2011, 35, 1027-1031.	0.4	7
139	Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology, 2011, 16, 278-283.	0.7	26
140	A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica, 2011, 96, 245-252.	1.7	62
141	Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica, 2010, 95, 324-328.	1.7	98
142	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood, 2010, 115, 1690-1696.	0.6	232
143	Which AML subsets benefit from leukemic cell priming during chemotherapy? Longâ€term analysis of the ALFAâ€9802 GMâ€CSF study. Cancer, 2010, 116, 1725-1732.	2.0	23
144	Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. Journal of Clinical Oncology, 2010, 28, 808-814.	0.8	209

#	Article	IF	Citations
145	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
146	Leukemia Stem Cells and New Strategies to Overcome Resistance to Therapy. Current Stem Cell Research and Therapy, 2010, 5, 277-286.	0.6	7
147	Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncology, 2009, 5, 1197-1210.	1.1	8
148	Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience. Journal of Clinical Oncology, 2009, 27, 2668-2676.	0.8	90
149	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosomeâ€"Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. Journal of Clinical Oncology, 2009, 27, 911-918.	0.8	506
150	The rationale and use of hypomethylation agents in adult acute myeloid leukemia. Expert Opinion on Drug Discovery, 2009, 4, 195-205.	2.5	1
151	Chemotherapy of acute leukemia in adults. Expert Opinion on Pharmacotherapy, 2009, 10, 221-237.	0.9	20
152	Book Review - Innovative Leukemia and Lymphoma Therapy. Immunotherapy, 2009, 1, 341-343.	1.0	0
153	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood, 2009, 113, 5090-5093.	0.6	87
154	NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood, 2009, 113, 3918-3924.	0.6	207
155	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood, 2009, 114, 1166-1173.	0.6	129
156	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood, 2009, 114, 4027-4033.	0.6	52
157	Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia. World Journal of Stem Cells, 2009, 1, 49.	1.3	5
158	Arsenic: a beneficial therapeutic poison - a historical overview. Adler Museum Bulletin, 2009, 35, 3-13.	0.3	8
159	The role of timed sequential chemotherapy in adult acute myelogenous leukemia. Current Hematologic Malignancy Reports, 2008, 3, 89-95.	1.2	1
160	Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. Cancer, 2008, 112, 572-580.	2.0	42
161	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group. Leukemia Research, 2008, 32, 1741-1750.	0.4	50
162	New emerging applications of molgramostim in acute myeloid leukaemia. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 795-806.	1.5	3

#	Article	IF	Citations
163	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer, 2008, 8, 195.	1.1	46
164	Conventional Therapy in Adult Acute Lymphoblastic Leukemia: Review of the LALA Program. , 2008, , 145-159.		1
165	Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. Clinical Leukemia, 2008, 2, 198-204.	0.2	11
166	Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology, 2008, 13, 293-302.	0.7	36
167	Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 2008, 49, 1246-1254.	0.6	5
168	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008, 111, 1078-1084.	0.6	156
169	Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica, 2008, 93, 1806-1813.	1.7	131
170	Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood, 2007, 110, 2324-2330.	0.6	60
171	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomeâ€"positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, 109, 1408-1413.	0.6	300
172	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood, 2007, 109, 5129-5135.	0.6	160
173	Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology, 2007, 12, 15-28.	0.7	8
174	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study. Haematologica, 2007, 92, 389-396.	1.7	48
175	Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program. Cancer, 2007, 109, 2058-2067.	2.0	11
176	Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALAâ€87 and LALAâ€94 trials. Cancer, 2007, 110, 2747-2755.	2.0	22
177	Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. European Journal of Haematology, 2006, 77, 471-479.	1.1	19
178	Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology, 2006, 24, 5703-5710.	0.8	162
179	Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.. Blood, 2006, 108, 147-147.	0.6	12
180	Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica, 2006, 91, 996-7.	1.7	29

#	Article	IF	Citations
181	Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood, 2005, 105, 3072-3078.	0.6	63
182	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood, 2005, 106, 27-34.	0.6	146
183	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 2005, 106, 3618-3620.	0.6	208
184	Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leukemia Research, 2005, 29, 1049-1058.	0.4	123
185	Acute leukemia during pregnancy. Cancer, 2005, 104, 110-117.	2.0	136
186	Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. Annals of Hematology, 2005, 84, 376-382.	0.8	10
187	Emerging drugs for adult acute lymphoblastic leukaemia. Expert Opinion on Emerging Drugs, 2005, 10, 591-617.	1.0	7
188	Heat shock proteins and acute leukemias. Hematology, 2005, 10, 225-235.	0.7	30
189	Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial. Journal of Clinical Oncology, 2004, 22, 4075-4086.	0.8	480
190	Cigarette Smoking and Acute Leukemia. Leukemia and Lymphoma, 2004, 45, 1103-1109.	0.6	32
191	Efficacy of granulocyte and granulocyteâ€“macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. The Hematology Journal, 2004, 5, 384-394.	2.0	20
192	Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Elderly: Prognostic Factors and Treatment Outcome. Hematology, 2004, 9, 369-376.	0.7	19
193	A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). Blood, 2004, 104, 2444-2451.	0.6	76
194	Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood, 2004, 104, 2467-2474.	0.6	78
195	Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. Journal of Clinical Oncology, 2003, 21, 774-780.	0.8	552
196	Prognostic Factors in Adult Acute Lymphoblastic Leukemia. Hematology, 2003, 8, 233-242.	0.7	16
197	A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood, 2002, 99, 3517-3523.	0.6	170
198	Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002, 100, 2717-2723.	0.6	476

#	Article	IF	Citations
199	Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial. Blood, 2002, 100, 2357-2366.	0.6	344
200	Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. Leukemia Research, 2002, 26, 909-918.	0.4	20
201	All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. The Hematology Journal, 2002, 3, 49-55.	2.0	32
202	Acute lymphoblastic leukemia in the elderly: The Edouard Herriot hospital experience. American Journal of Hematology, 2001, 67, 73-83.	2.0	69
203	ADULT ACUTE LYMPHOCYTIC LEUKEMIA STUDY TESTING CHEMOTHERAPY AND AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION. Hematology/Oncology Clinics of North America, 2000, 14, 1353-1366.	0.9	160
204	Prognostic Factors in Acute Promyelocytic Leukemia: A Retrospective Study of 67 Cases. Leukemia and Lymphoma, 1991, 4, 249-256.	0.6	44